© 2023 MJH Life Sciences and Cannabis Science and Technology . All rights reserved.
© 2023 MJH Life Sciences™ , Cannabis Science and Technology . All rights reserved.
August 31, 2023
On Wednesday, August 30th, the Department of Health and Human Services made its recommendation to the Drug Enforcement Agency to classify cannabis as a Schedule III drug, paving the way for reform, industry expansion, and research opportunities.
August 29, 2023
The recently approved legislation creates new opportunities for possession and cultivation.
June 29, 2023
Several agencies are reportedly working together to review the scheduling of cannabis, with a final decision anticipated to come later this year.
June 23, 2023
The New Jersey Business Action Center (NJBCA) recently announced Tauhid Chappell as the first Executive Director of its Cannabis Training Academy (CTA).
June 12, 2023
If passed, possession of psilocybin would be legal in certain circumstances in the state.
June 08, 2023
Sponsored by 17 state lawmakers, House resolution 420 called on federal officials to reschedule cannabis at the federal level.
June 01, 2023
After the most recent cannabis legalization bill failed to pass the Senate, Governor Sununu issued a statement explaining how legalization could occur instead.
March 10, 2023
In early March 2023, the US Justice Department launched an online application for individuals who were pardoned for simple possession of cannabis under President Biden's October 6, 2022 proclamation. Applicants can now receive a certificate of proof of their pardon.
February 20, 2023
The House and Senate introduced a revised bill to mandate Veterans Affairs (VA) to conduct research on the effects of medical cannabis on veterans with post-traumatic stress disorder (PTSD) and chronic pain.
January 27, 2023
A statement released on Thursday, January 26, 2023 from Dr. Janet Woodcock, the principal deputy commissioner of the Food and Drug Administration (FDA), announced that the FDA will work with Congress in formulating regulatory oversight to balance risk and access for products in the cannabidiol (CBD) market.